Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma

被引：0

作者：

Wang, Q. ^{[1
]}

Chai, X. ^{[2
]}

Lin, R. ^{[3
]}

Zheng, L. ^{[4
]}

Cao, D. ^{[5
]}

Qu, X. ^{[6
]}

Liu, L. ^{[7
]}

Wu, L. ^{[8
]}

Mou, H. ^{[9
]}

Xu, Q. ^{[10
]}

Shi, J. ^{[11
]}

机构：

[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China

[2] ChangSha TaiHe Hosp, Dept Oncol, Changsha, Peoples R China

[3] Fujian Canc Hosp, Dept Abdominal Oncol, Fujian, Peoples R China

[4] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China

[5] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China

[6] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[7] Jilin Univ, China Japan Union Hosp, Phase Clin Trial Ctr 1, Changchun, Peoples R China

[8] Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China

[9] Shulan Hangzhou Hosp, Dept Oncol, Hangzhou, Peoples R China

[10] Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Gastroenterol, Hangzhou, Peoples R China

[11] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.752

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

686TiP

引用

页码：S532 / S533

页数：2

共 50 条

[31] Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
Borghaei, H.
Paz-Ares, L.
Johnson, M.
Champiat, S.
Owonikoko, T.
Lai, V.
Boyer, M.
Hummel, H. -D.
Govindan, R.
Steeghs, N.
Blackhall, F.
Reguart, N.
Dowlati, A.
Zhang, Y.
Sadraei, N. Hashemi
Goldrick, A.
Izumi, H.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S33 - S33
[32] CLINICAL PHARMACOLOGY CHARACTERIZATION OF AMG 119, A CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING DELTA-LIKE LIGAND 3 (DLL3), IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
Zhou, D.
Byers, L.
Sable, B.
Smit, M.
Sadraei, N. Hashemi
Dutta, S.
Upreti, V.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S61 - S61
[33] PHARMACOKIN ETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Minocha, M.
Thompson, C.
Murphy, A.
Zhou, Y.
Parkes, A.
Chen, X.
Yu, B.
Martinez, P.
Houk, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S68 - S68
[34] Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
Paz-Ares, Luis G.
Felip, Enriqueta
Ahn, Myung-Ju
Blackhall, Fiona Helen
Borghaei, Hossein
Cho, Byoung Chul
Johnson, Melissa Lynne
Ramalingam, Suresh S.
Reck, Martin
Zhang, Alicia
Ju, Chia-Hsin
Minocha, Mukul
Mukherjee, Sujoy
Suri, Gaurav
Jandial, Danielle
Bebb, D. Gwyn
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[35] Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)
Cooke, Keegan
Estrada, Juan
Zhan, Jinghui
Werner, Jonathan
Caenepeel, Sean
Giffin, Mike
Bailis, Julie M.
Coxon, Angela
Hughes, Paul E.
Canon, Jude
CANCER RESEARCH, 2020, 80 (16)
[36] DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas
Capdevila, Jaume
Vandamme, Timon
Niccoli, Patricia
Mishima, Saori
Kato, Ken
Ma, Yiyuan
Sun, Ping
Geng, Lijiang
Lauer, Ulrich M.
CANCER RESEARCH, 2024, 84 (07)
[37] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Paz-Ares, Luis
Champiat, Stephane
Lai, W. Victoria
Izumi, Hiroki
Govindan, Ramaswamy
Boyer, Michael
Hummel, Horst-Dieter
Borghaei, Hossein
Johnson, Melissa L.
Steeghs, Neeltje
Blackhall, Fiona
Dowlati, Afshin
Reguart, Noemi
Yoshida, Tatsuya
He, Kai
Gadgeel, Shirish M.
Felip, Enriqueta
Zhang, Yiran
Pati, Amrita
Minocha, Mukul
Mukherjee, Sujoy
Goldrick, Amanda
Nagorsen, Dirk
Sadraei, Nooshin Hashemi
Owonikoko, Taofeek K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2893 - 2903
[38] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Aggarwal, Rahul Raj
Rottey, Sylvie
Aparicio, Ana
Greil, Richard
Reimers, Melissa Andrea
Sandhu, Shahneen Kaur
Zhang, Yiran
Salvati, Mark
Sadraei, Nooshin Hashemi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[39] DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
Gambardella, Valentina
Greystoke, Alastair
Reck, Martin
Liu, Meiruo
Mueller, Martha
Duenzinger, Ulrich
Bergsland, Emily B.
Owonikoko, Taofeek
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[40] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Minocha, Mukul
Thompson, Corbin G.
Murphy, Alexis
Zhou, Yanchen
Brandl, Christian
Parkes, Amanda
Chen, Xi
Yu, Brian
Martinez, Pablo
Houk, Brett E.
CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768

← 1 2 3 4 5 →